Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial by Uhrenholt, L, Sørensen, MER, Lauridsen, KB, Duch, K, Dreyer, L, Christensen, R, Hauge, E-M, Loft, AG, Rasch, MNB, Horn, HC, Taylor, PC, Nielsen, KR, Kristensen, S